Both Johnson & Johnson JNJ and Merck MRK are leading U.S. healthcare conglomerates — blue-chip pharmaceutical companies with ...

The Dow Jones Industrial Average (DJINDICES: ^DJI) is loaded with blue chip stocks. It stands to reason that many Dow stocks ...

Merck scored a major win with FDA approval for Enflonsia, its fresh RSV-fighting antibody aimed at shielding infants. This ...

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Major vaccine policy changes could be on the horizon as the HHS removes key advisors. Click for my thoughts on what this may ...

Merck’s stock showed a slight pulse this week, with a 0.41% daily rise and a 4.31% gain over five days, prompting cautious ...

The S&P 500 ended slightly higher on Monday (June 9), extending its gains for a second session, as markets reacted to renewed ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

U.S. Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick and Trade Representative Jamieson Greer will meet with top-level Chinese officials, Trump said last week.

Merck, which is evaluating the safety and efficacy of enlicitide for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin, said the Phase 3 studies met ...